@article {949, title = {A relatively common homozygous TRAPPC4 splicing variant is associated with an early-infantile neurodegenerative syndrome.}, journal = {Eur J Hum Genet}, volume = {29}, year = {2021}, month = {2021 Feb}, pages = {271-279}, abstract = {

Trafficking protein particle (TRAPP) complexes, which include the TRAPPC4 protein, regulate membrane trafficking between lipid organelles in a process termed vesicular tethering. TRAPPC4 was recently implicated in a recessive neurodevelopmental condition in four unrelated families due to a shared c.454+3A>G splice variant. Here, we report 23 patients from 17 independent families with an early-infantile-onset neurodegenerative presentation, where we also identified the homozygous variant hg38:11:119020256 A>G (NM_016146.5:c.454+3A>G) in TRAPPC4 through exome or genome sequencing. No other clinically relevant TRAPPC4 variants were identified among any of over 10,000 patients with neurodevelopmental conditions. We found the carrier frequency of TRAPPC4 c.454+3A>G was 2.4-5.4 per 10,000 healthy individuals. Affected individuals with the homozygous TRAPPC4 c.454+3A>G variant showed profound psychomotor delay, developmental regression, early-onset epilepsy, microcephaly and progressive spastic tetraplegia. Based upon RNA sequencing, the variant resulted in partial exon 3 skipping and generation of an aberrant transcript owing to use of a downstream cryptic splice donor site, predicting a premature stop codon and nonsense mediated decay. These data confirm the pathogenicity of the TRAPPC4 c.454+3A>G variant, and refine the clinical presentation of TRAPPC4-related encephalopathy.

}, issn = {1476-5438}, doi = {10.1038/s41431-020-00717-5}, author = {Ghosh, Shereen G and Scala, Marcello and Beetz, Christian and Helman, Guy and Stanley, Valentina and Yang, Xiaoxu and Breuss, Martin W and Mazaheri, Neda and Selim, Laila and Hadipour, Fatemeh and Pais, Lynn and Stutterd, Chloe A and Karageorgou, Vasiliki and Begtrup, Amber and Crunk, Amy and Juusola, Jane and Willaert, Rebecca and Flore, Leigh A and Kennelly, Kelly and Spencer, Christopher and Brown, Martha and Trapane, Pamela and Hurst, Anna C E and Lane Rutledge, S and Goodloe, Dana H and McDonald, Marie T and Shashi, Vandana and Schoch, Kelly and Tomoum, Hoda and Zaitoun, Raghda and Hadipour, Zahra and Galehdari, Hamid and Pagnamenta, Alistair T and Mojarrad, Majid and Sedaghat, Alireza and Dias, Patr{\'\i}cia and Quintas, Sofia and Eslahi, Atiyeh and Shariati, Gholamreza and Bauer, Peter and Simons, Cas and Houlden, Henry and Issa, Mahmoud Y and Zaki, MAH S and Maroofian, Reza and Gleeson, Joseph G} } @article {799, title = {NEMF mutations that impair ribosome-associated quality control are associated with neuromuscular disease.}, journal = {Nat Commun}, volume = {11}, year = {2020}, month = {2020 09 15}, pages = {4625}, abstract = {

A hallmark of neurodegeneration is defective protein quality control. The E3 ligase Listerin (LTN1/Ltn1) acts in a specialized protein quality control pathway-Ribosome-associated Quality Control (RQC)-by mediating proteolytic targeting of incomplete polypeptides produced by ribosome stalling, and Ltn1 mutation leads to neurodegeneration in mice. Whether neurodegeneration results from defective RQC and whether defective RQC contributes to human disease have remained unknown. Here we show that three independently-generated mouse models with mutations in a different component of the RQC complex, NEMF/Rqc2, develop progressive motor neuron degeneration. Equivalent mutations in yeast Rqc2 selectively interfere with its ability to modify aberrant translation products with C-terminal tails which assist with RQC-mediated protein degradation, suggesting a pathomechanism. Finally, we identify NEMF mutations expected to interfere with function in patients from seven families presenting juvenile neuromuscular disease. These uncover NEMF{\textquoteright}s role in translational homeostasis in the nervous system and implicate RQC dysfunction in causing neurodegeneration.

}, keywords = {Amino Acid Sequence, Animals, Female, Humans, Male, Mice, Mice, Knockout, Mutation, Neuromuscular Diseases, Proteolysis, Ribosomes, RNA-Binding Proteins, Saccharomyces cerevisiae, Saccharomyces cerevisiae Proteins, Sequence Alignment}, issn = {2041-1723}, doi = {10.1038/s41467-020-18327-6}, author = {Martin, Paige B and Kigoshi-Tansho, Yu and Sher, Roger B and Ravenscroft, Gianina and Stauffer, Jennifer E and Kumar, Rajesh and Yonashiro, Ryo and M{\"u}ller, Tina and Griffith, Christopher and Allen, William and Pehlivan, Davut and Harel, Tamar and Zenker, Martin and Howting, Denise and Schanze, Denny and Faqeih, Eissa A and Almontashiri, Naif A M and Maroofian, Reza and Houlden, Henry and Mazaheri, Neda and Galehdari, Hamid and Douglas, Ganka and Posey, Jennifer E and Ryan, Monique and Lupski, James R and Laing, Nigel G and Joazeiro, Claudio A P and Cox, Gregory A} } @article {716, title = {Homozygous Missense Variants in NTNG2, Encoding a Presynaptic Netrin-G2 Adhesion Protein, Lead to a Distinct Neurodevelopmental Disorder.}, journal = {Am J Hum Genet}, volume = {105}, year = {2019}, month = {2019 Nov 07}, pages = {1048-1056}, abstract = {

NTNG2 encodes netrin-G2, a membrane-anchored protein implicated in the molecular organization of neuronal circuitry and synaptic organization and diversification in vertebrates. In this study, through a combination of exome sequencing and autozygosity mapping, we have identified 16 individuals (from seven unrelated families) with ultra-rare homozygous missense variants in NTNG2; these individuals present with shared features of a neurodevelopmental disorder consisting of global developmental delay, severe to profound intellectual disability, muscle weakness and abnormal tone, autistic features, behavioral abnormalities, and variable dysmorphisms. The variants disrupt highly conserved residues across the protein. Functional experiments, including in silico analysis of the protein structure, in~vitro assessment of cell surface expression, and in~vitro knockdown, revealed potential mechanisms of pathogenicity of the variants, including loss of protein function and decreased neurite outgrowth. Our data indicate that appropriate expression of NTNG2 plays an important role in neurotypical development.

}, issn = {1537-6605}, doi = {10.1016/j.ajhg.2019.09.025}, author = {Dias, Caroline M and Punetha, Jaya and Zheng, C{\'e}line and Mazaheri, Neda and Rad, Abolfazl and Efthymiou, Stephanie and Petersen, Andrea and Dehghani, Mohammadreza and Pehlivan, Davut and Partlow, Jennifer N and Posey, Jennifer E and Salpietro, Vincenzo and Gezdirici, Alper and Malamiri, Reza Azizi and Al Menabawy, Nihal M and Selim, Laila A and Vahidi Mehrjardi, Mohammad Yahya and Banu, Selina and Polla, Daniel L and Yang, Edward and Rezazadeh Varaghchi, Jamileh and Mitani, Tadahiro and van Beusekom, Ellen and Najafi, Maryam and Sedaghat, Alireza and Keller-Ramey, Jennifer and Durham, Leslie and Coban-Akdemir, Zeynep and Karaca, Ender and Orlova, Valeria and Schaeken, Lieke L M and Sherafat, Amir and Jhangiani, Shalini N and Stanley, Valentina and Shariati, Gholamreza and Galehdari, Hamid and Gleeson, Joseph G and Walsh, Christopher A and Lupski, James R and Seiradake, Elena and Houlden, Henry and van Bokhoven, Hans and Maroofian, Reza} } @article {585, title = {Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy.}, journal = {J Clin Invest}, volume = {129}, year = {2019}, month = {2019 Mar 01}, pages = {1240-1256}, abstract = {

Sphingolipid imbalance is the culprit in a variety of neurological diseases, some affecting the myelin sheath. We have used whole-exome sequencing in patients with undetermined leukoencephalopathies to uncover the endoplasmic reticulum lipid desaturase DEGS1 as the causative gene in 19 patients from 13 unrelated families. Shared features among the cases include severe motor arrest, early nystagmus, dystonia, spasticity, and profound failure to thrive. MRI showed hypomyelination, thinning of the corpus callosum, and progressive thalamic and cerebellar atrophy, suggesting a critical role of DEGS1 in myelin development and maintenance. This enzyme converts dihydroceramide (DhCer) into ceramide (Cer) in the final step of the de novo biosynthesis pathway. We detected a marked increase of the substrate DhCer and DhCer/Cer ratios in patients{\textquoteright} fibroblasts and muscle. Further, we used a knockdown approach for disease modeling in Danio rerio, followed by a preclinical test with the first-line treatment for multiple sclerosis, fingolimod (FTY720, Gilenya). The enzymatic inhibition of Cer synthase by fingolimod, 1 step prior to DEGS1 in the pathway, reduced the critical DhCer/Cer imbalance and the severe locomotor disability, increasing the number of myelinating oligodendrocytes in a zebrafish model. These proof-of-concept results pave the way to clinical translation.

}, issn = {1558-8238}, doi = {10.1172/JCI123959}, author = {Pant, Devesh C and Dorboz, Imen and Schluter, Agatha and Fourcade, St{\'e}phane and Launay, Nathalie and Joya, Javier and Aguilera-Albesa, Sergio and Yoldi, Maria Eugenia and Casasnovas, Carlos and Willis, Mary J and Ruiz, Montserrat and Ville, Doroth{\'e}e and Lesca, Gaetan and Siquier-Pernet, Karine and Desguerre, Isabelle and Yan, Huifang and Wang, Jingmin and Burmeister, Margit and Brady, Lauren and Tarnopolsky, Mark and Cornet, Carles and Rubbini, Davide and Terriente, Javier and James, Kiely N and Musaev, Damir and Zaki, Maha S and Patterson, Marc C and Lanpher, Brendan C and Klee, Eric W and Pinto E Vairo, Filippo and Wohler, Elizabeth and Sobreira, Nara Lygia de M and Cohen, Julie S and Maroofian, Reza and Galehdari, Hamid and Mazaheri, Neda and Shariati, Gholamreza and Colleaux, Laurence and Rodriguez, Diana and Gleeson, Joseph G and Pujades, Cristina and Fatemi, Ali and Boespflug-Tanguy, Odile and Pujol, Aurora} }